Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ECS Botanics HoldingsASX:ECS Equity-to-Asset is 0.72 as of Dec. 2025, which is 17% below its 10-year median of 0.87. The stock has 9 warning signs investors should review. Among 1,007 Drug Manufacturers companies, ECS Botanics Holdings ranks better than 67.43% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ECS Botanics Holdings Equity-to-Asset Related Terms
ECS Botanics Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for ECS Botanics Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ECS Botanics Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ECS Botanics Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ECS Botanics Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ECS Botanics Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ECS Botanics Holdings's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ECS Botanics Holdings (ASX:ECS) has a Equity-to-Asset of 0.72 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ECS Botanics Holdings and its competitors. This is 17% below median its historical median of 0.87. According to the industry distribution chart, ECS Botanics Holdings ranks #328 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 32.6%.
Is ECS Botanics Holdings' Equity-to-Asset too high?
ECS Botanics Holdings' current Equity-to-Asset of 0.72 is 17% below median its 10-year median of 0.87. The Drug Manufacturers industry median Equity-to-Asset is 0.61. ECS Botanics Holdings' value of 0.72 is 18% above this industry median. Based on the distribution chart, ECS Botanics Holdings ranks #328 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does ECS Botanics Holdings' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ECS Botanics Holdings ranks #328 out of 1007 companies for Equity-to-Asset. This puts ECS Botanics Holdings in the upper half of its industry. The industry median Equity-to-Asset is 0.61. ECS Botanics Holdings' value of 0.72 is 18% above this benchmark. While the company's 10-year median is 0.87 vs. the industry median of 0.61, ECS Botanics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ECS Botanics Holdings's current Equity-to-Asset of 0.72 is 18% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ECS Botanics Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ECS Botanics Holdings's current Equity-to-Asset is 0.72, which is 17% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ECS Botanics Holdings stock overvalued right now?
Based on GuruFocus' analysis, ECS Botanics Holdings (ASX:ECS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 70% below its estimated fair value. The current Equity-to-Asset is 0.72, which is 17% below median its 10-year median of 0.87 and 18% above the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For ECS Botanics Holdings (ASX:ECS), the current Equity-to-Asset is 0.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. The company utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, the company provides quality, affordable medicinal cannabis, supplying both local and overseas markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ECS has been successfully added to your 
